DLL3 CAR-T Therapy Targeting Brain Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

September 30, 2029

Conditions

Glioblastoma of Cerebellum

Interventions

BIOLOGICAL

4SCAR DLL3 T cells

Infusion of 4SCAR DLL3 T cells at 10\^6 cells/kg body weight via intravenous route

Trial Locations (1)

RECRUITING

Shenzhen Geno-immuno Medical Institute, Shenzhen

All Listed Sponsors

lead

Shenzhen Geno-Immune Medical Institute

OTHER

NCT07180927 - DLL3 CAR-T Therapy Targeting Brain Tumors | Biotech Hunter | Biotech Hunter